Cargando…

Treatment with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Dermatomyositis/Polymyositis

PURPOSE: Repository corticotropin injection (RCI) is indicated for a number of autoimmune-mediated diseases including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and dermatomyositis (DM)/polymyositis (PM). To better understand the practice patterns and outcomes of RCI in patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ho-Mahler, Nancy, Turner, Beni, Eaddy, Michael, Hanke, Mark L, Nelson, Winnie W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7039080/ https://www.ncbi.nlm.nih.gov/pubmed/32110122 http://dx.doi.org/10.2147/OARRR.S231667

Ejemplares similares

Medical resource utilization in dermatomyositis/polymyositis patients treated with repository corticotropin injection, intravenous immunoglobulin, and/or rituximab
por: Knight, Tyler, et al.
Publicado: (2017)

A Narrative Review of Repository Corticotropin Injection for the Treatment of Systemic Lupus Erythematosus
por: Askanase, Anca D., et al.
Publicado: (2022)

Repository corticotropin injection in patients with rheumatoid arthritis resistant to biologic therapies
por: Fischer, Peter A, et al.
Publicado: (2018)

Real-world treatment patterns for repository corticotropin injection in patients with rheumatoid arthritis
por: Busch, Howard, et al.
Publicado: (2022)

Cost-Effectiveness of Repository Corticotropin Injection versus Standard of Care for the Treatment of Active Rheumatoid Arthritis
por: Bindra, Jas, et al.
Publicado: (2021)

Post Hoc Analysis of Predictors of Clinical Response to Repository Corticotropin Injection in Persistently Active Rheumatoid Arthritis
por: Fleischmann, Roy, et al.
Publicado: (2022)

Nutrition and Polymyositis and Dermatomyositis
por: Loell, Ingela, et al.
Publicado: (2008)

Repository Corticotropin Injection for Treatment of Idiopathic Inflammatory Myopathies
por: Patel, Aarat, et al.
Publicado: (2016)

Treatment of fibrillary glomerulonephritis with use of repository corticotropin injections
por: Maroz, Natallia, et al.
Publicado: (2018)

Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial
por: Fleischmann, Roy, et al.
Publicado: (2020)

Viral Etiology of Polymyositis/Dermatomyositis
por: DENMAN, A.M.
Publicado: (1988)

Subcutaneous Edema in Polymyositis and Dermatomyositis
por: Yoshimi, Ryusuke, et al.
Publicado: (2023)

Repository corticotropin injection in patients with refractory psoriatic arthritis: a case series
por: Brown, Alan N
Publicado: (2016)

Patient Characteristics and Indicators of Treatment Initiation with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis: A Claims Database Analysis
por: Hayes, Kyle, et al.
Publicado: (2021)

Medication Utilization Patterns 90 Days Before Initiation of Treatment with Repository Corticotropin Injection in Patients with Infantile Spasms
por: Gold, Laura S, et al.
Publicado: (2019)

Retrospective Medical Record Review to Describe Use of Repository Corticotropin Injection Among Patients with Uveitis in the United States
por: Nelson, Winnie W., et al.
Publicado: (2019)

Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
por: Askanase, Anca D., et al.
Publicado: (2020)

Repository corticotropin injection in a patient presenting with focal segmental glomerulosclerosis, rheumatoid arthritis, and optic neuritis: a case report
por: Madan, Arvind
Publicado: (2015)

Polymyositis and dermatomyositis: Disease spectrum and classification
por: Raychaudhuri, Siba P, et al.
Publicado: (2012)

Polymyositis and dermatomyositis – challenges in diagnosis and management
por: Yang, Shu-Han, et al.
Publicado: (2019)

Dermatomyositis and polymyositis in total hip arthroplasty
por: Rosas, Samuel, et al.
Publicado: (2021)

Treatment of Noninfectious Retinal Vasculitis Using Subcutaneous Repository Corticotropin Injection
por: Anesi, Stephen D., et al.
Publicado: (2021)

Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis: A Narrative Review
por: Mirsaeidi, Mehdi, et al.
Publicado: (2022)

Correction to: Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
por: Askanase, Anca D., et al.
Publicado: (2021)

Repository corticotropin for Chronic Pulmonary Sarcoidosis
por: Baughman, Robert P., et al.
Publicado: (2017)

Real-World Treatment Patterns and Outcomes from an Electronic Medical Records Database for Patients with Rheumatoid Arthritis Treated with Repository Corticotropin Injection
por: Hayes, Kyle, et al.
Publicado: (2021)

Post Hoc Analysis of the Correlation Between Patient-Reported Outcomes and Clinical Response to Repository Corticotropin Injection for Persistently Active Rheumatoid Arthritis
por: Fleischmann, Roy, et al.
Publicado: (2021)

Cost-Effectiveness of Repository Corticotropin Injection for the Treatment of Acute Exacerbations in Multiple Sclerosis
por: Hunter, Samuel F, et al.
Publicado: (2021)

Polymyositis and dermatomyositis as a risk of developing cancer
por: Jakubaszek, Michał, et al.
Publicado: (2015)

Cardiac involvement in polymyositis and dermatomyositis: diagnostic approaches
por: Trybuch, Agnieszka, et al.
Publicado: (2023)

Repository corticotropin injection as adjunctive therapy in patients with rheumatoid arthritis who have failed previous therapies with at least three different modes of action
por: Gillis, Theresa, et al.
Publicado: (2017)

Circulating plasma microRNA profiling in patients with polymyositis/dermatomyositis before and after treatment: miRNA may be associated with polymyositis/dermatomyositis
por: Hirai, Takuya, et al.
Publicado: (2018)

Repository corticotropin injection in patients with advanced symptomatic sarcoidosis: retrospective analysis of medical records
por: Chopra, Ishveen, et al.
Publicado: (2019)

Repository Corticotropin Injections Promote Clinical Remission and Regulatory T Cell Expansion in Membranous Nephropathy
por: Hartzell, Susan, et al.
Publicado: (2021)

Potential role of autophagy in T-cell survival in polymyositis and dermatomyositis
por: Shu, Xiaoming, et al.
Publicado: (2017)

Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar(®) Gel) for Persistently Active Systemic Lupus Erythematosus
por: Askanase, Anca D., et al.
Publicado: (2021)

A Retrospective Medical Record Review of Utilization Patterns and Medical Resource Use Associated with Repository Corticotropin Injection among Patients with Rheumatologic Diseases in the United States
por: Nelson, Winnie W., et al.
Publicado: (2017)

H.P. Acthar Gel (repository corticotropin injection) treatment of patients with multiple sclerosis and diabetes
por: Kutz, Christen
Publicado: (2016)

Pharmacodynamics and tolerability of repository corticotropin injection in healthy human subjects: A comparison with intravenous methylprednisolone
por: Lal, Ritu, et al.
Publicado: (2015)

Understanding Predictors of Response to Repository Corticotropin Injection Treatment Among Patients With Advanced Symptomatic Sarcoidosis
por: Bindra, Jas, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qfpj0lr041454rcnjp9i30kp0l